Iodine-125 brachytherapy alone for advanced primary parotid gland carcinoma

Zhou, Chuan‐Xiang; Zhang, J.; Zhang, J.-G.; Liu, S.-M.; Zheng, Lei; Huang, Mianliang; Shi, Yan; Lv, Xianli

doi:10.1016/j.ijom.2017.03.038

Cited by 2 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On multivariate analysis, we found age ≥ 60 years and T4 disease to be independent predictors of local control failure. Earlier studies have shown high histological grade, advanced T classification, positive surgical margins, and older age to be prognostic factors . In one study of primary parotid gland carcinoma treated with 125 I seed brachytherapy alone, the survival rate of older patients (≥60 years) was significantly lower than that of younger patients (<60 years) .…”

Section: Discussionmentioning

confidence: 99%

“…10,12,14,17 In one study of primary parotid gland carcinoma treated with 125 I seed brachytherapy alone, the survival rate of older patients (≥60 years) was significantly lower than that of younger patients (<60 years). 10 Cederblad et al 19 investigated 144 patients with parotid gland carcinoma and reported the 5-year survival rate in patients >65 years to be significantly lower than that of patients <65 years (P < .01). T classification has also been identified as a significant prognostic factor in MEC.…”

Section: Discussionmentioning

confidence: 99%

“…Earlier studies have shown high histological grade, advanced T classification, positive surgical margins, and older age to be prognostic factors. 10,12,14,17 In one study of primary parotid gland carcinoma treated with 125 I seed brachytherapy alone, the survival rate of older patients (≥60 years) was significantly lower than that of younger patients (<60 years). 10 Cederblad et al 19 investigated 144 patients with parotid gland carcinoma and reported the 5-year survival rate in patients >65 years to be significantly lower than that of patients <65 years (P < .01).…”

Section: Discussionmentioning

confidence: 99%

“…However, external radiotherapy of the parotid region is associated with many toxicities, including skin and auditory toxicity, xerostomia, and osteoradionecrosis . Theoretically, most of these toxicities of parotid region could be minimized with the use of 125 I seed brachytherapy, with which it is possible to deliver high dose to the tumor volume while sparing surrounding tissue . The aim of this retrospective study was to explore the efficacy and safety of surgery combined with postoperative 125 I seed brachytherapy for treatment of MEC of the parotid gland and to identify the factors influencing outcomes.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of combined surgery and ¹²⁵I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Zheng

et al. 2019

Head & Neck

View full text Add to dashboard Cite

Background This study aimed to determine the effectiveness and safety of surgery combined with postoperative 125I seed brachytherapy for treatment of primary mucoepidermoid carcinoma (MEC) of the parotid gland. Methods Retrospective analysis of data of patients with MEC (n = 108) treated with surgery plus postoperative 125I seed brachytherapy between 2004 and 2016. Overall survival (OS), disease‐free survival (DFS), local control rate (LCR), distant metastasis, and radiation‐associated toxicities were analyzed, and factors affecting outcomes were evaluated. Results The 5‐ and 10‐year OS were 98.8% and 95.8%, respectively. The DFS and LCR at 5 and 10 years were all 91.4%. Age ≥ 60 years (hazard ratio [HR] = 6.86, 95% confidence interval [CI]: 1.54‐30.55) and T4 disease (HR = 7.15, 95% CI: 1.40‐36.52) were poor prognostic factors. Acute radiation‐associated toxicities were minor. Conclusion Surgery plus 125I seed brachytherapy appears to be an effective treatment for parotid gland MEC, capable of providing satisfactory outcomes with few complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of combined surgery and ¹²⁵I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Zheng

et al. 2019

Head & Neck

View full text Add to dashboard Cite

show abstract

Comparison of outcomes using radiotherapy or brachytherapy after resection of primary adenoid cystic carcinoma in oral and maxillofacial regions

Liu

Zheng

et al. 2021

Brachytherapy

Self Cite

View full text Add to dashboard Cite

We wished to investigate the outcome of surgery combined with external-beam radiotherapy (EBRT) or brachytherapy (125 I seeds) for the treatment of primary adenoid cystic carcinoma (ACC) of the oral and maxillofacial region. Data of patients with primary ACC were reviewed retrospectively. Patients were divided into EBRT and brachytherapy groups. Wide tumor excision was done to achieve negative margins. Standard radiotherapy in the EBRT group was 60 Gy. A treatment-planning system was used to create implantation plans with a prescribed dose of 60e 120 Gy and 125 I seeds were implanted postoperatively. KaplaneMeier method and log-rank tests were used to analyze local control and survival. The median duration of followup was 66.1 and 46.8 months for the EBRT group and brachytherapy group, respectively. There was no significant difference in local control, control of metastasis to regional lymph nodes, or control of distant metastasis between the two groups. There was no significant difference in overall survival, disease-specific survival, or disease-free survival in the two groups at 3 years and 5 years. The prevalence of complications in the brachytherapy group was lower than that in the EBRT group. Both methods elicited good treatment effects, but the prevalence of adverse events was lower in the brachytherapy group.

show abstract

Iodine-125 brachytherapy alone for advanced primary parotid gland carcinoma

Cited by 2 publications

References 27 publications

Efficacy of combined surgery and ¹²⁵I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Efficacy of combined surgery and ¹²⁵I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Comparison of outcomes using radiotherapy or brachytherapy after resection of primary adenoid cystic carcinoma in oral and maxillofacial regions

Contact Info

Product

Resources

About

Iodine-125 brachytherapy alone for advanced primary parotid gland carcinoma

Cited by 2 publications

References 27 publications

Efficacy of combined surgery and 125I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Efficacy of combined surgery and 125I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Comparison of outcomes using radiotherapy or brachytherapy after resection of primary adenoid cystic carcinoma in oral and maxillofacial regions

Contact Info

Product

Resources

About

Efficacy of combined surgery and ¹²⁵I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Efficacy of combined surgery and ¹²⁵I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland